Retatrutide (60mg)

Bulk Research Vial — Triple-Agonist Format (60mg)

Retatrutide (60mg) is supplied in Australia by Aussie Peptides with fast domestic shipping to all states and territories.

The 60mg vial supports full-length Retatrutide research protocols in a single batch. Six times the compound of the 10mg vial, at the lowest price per milligram. Same ≥99% purity standard and batch-verified CoA.

Phase 2 clinical trials reported a mean body weight reduction of up to 24% over 48 weeks — outperforming semaglutide and tirzepatide. Retatrutide’s triple-receptor activity simultaneously targets GLP-1 (appetite), GIP (insulin sensitivity), and glucagon (energy expenditure), making it the most-studied tri-agonist in current weight-research literature.

Key Research Areas

• Fat Loss Research — including visceral adiposity
• Appetite Regulation — reduced food intake and caloric studies
• Metabolic Markers — blood pressure, lipids, waist circumference
• Energy Expenditure — via glucagon receptor activation
• Comparative Research — outperforms semaglutide and tirzepatide in head-to-head data

Supplied as lyophilized powder at ≥99% purity, verified by HPLC and mass spectrometry. 60mg per vial. Fast domestic shipping across Australia, with batch-specific CoA information available in our CoA Library.

⚠ For in-vitro research and laboratory use only. Not for human consumption.